2395 Stock Overview
A contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,019.00 |
| 52 Week High | JP¥2,355.00 |
| 52 Week Low | JP¥970.00 |
| Beta | -0.012 |
| 11 Month Change | -22.45% |
| 3 Month Change | -27.32% |
| 1 Year Change | -56.15% |
| 33 Year Change | 17.94% |
| 5 Year Change | 64.62% |
| Change since IPO | -53.47% |
Recent News & Updates
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09
Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Recent updates
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Shareholder Returns
| 2395 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -12.3% | -5.6% | -2.1% |
| 1Y | -56.2% | -44.7% | 6.1% |
Return vs Industry: 2395 underperformed the JP Life Sciences industry which returned -44.8% over the past year.
Return vs Market: 2395 underperformed the JP Market which returned 5.2% over the past year.
Price Volatility
| 2395 volatility | |
|---|---|
| 2395 Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in JP Market | 9.9% |
| 10% least volatile stocks in JP Market | 3.3% |
Stable Share Price: 2395's share price has been volatile over the past 3 months.
Volatility Over Time: 2395's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,445 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| 2395 fundamental statistics | |
|---|---|
| Market cap | JP¥42.42b |
| Earnings (TTM) | JP¥4.28b |
| Revenue (TTM) | JP¥26.20b |
9.9x
P/E Ratio1.6x
P/S RatioIs 2395 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2395 income statement (TTM) | |
|---|---|
| Revenue | JP¥26.20b |
| Cost of Revenue | JP¥13.41b |
| Gross Profit | JP¥12.78b |
| Other Expenses | JP¥8.50b |
| Earnings | JP¥4.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 102.81 |
| Gross Margin | 48.79% |
| Net Profit Margin | 16.34% |
| Debt/Equity Ratio | 100.0% |
How did 2395 perform over the long term?
See historical performance and comparisonDividends
4.9%
Current Dividend Yield49%
Payout RatioDoes 2395 pay a reliable dividends?
See 2395 dividend history and benchmarks| Shin Nippon Biomedical Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 114 days |
Does 2395 pay a reliable dividends?
See 2395 dividend history and benchmarks